AUTL · Autolus Therapeutics plc
Market Cap
$493.73M
Shares
266.16M
Volume · Oct 6
1.68M
Avg daily vol (3M)
2.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.79
Open$1.84
Day$1.76–1.87
52W close$1.21–2.54
Avg vol 30d1.6M
Short int8.3M · 3.1% float · 4.8d
Short vol54%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
call held May 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$117.39M
Trailing 12 months
Net income (TTM)
−$280.16M
Trailing 12 months
Revenue growth YoY
+118.4%
Year over year
Operating margin
-210.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+13.7%
Trailing year
Short interest
3.1%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−12%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+20%
trailing
YTD return
−10%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
1 of 83 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$15.7K over 90 days · 100% sells
Short interest
Falling
3.13% of float · ▼ -8.4% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+496%
Y/Y
EPS growth
−26%
Y/Y
Free cash flow
$-302.6M
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
AUCATZYL net product revenue
· full year 2026
Initiated
$140M – $150M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
1 of 83 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$15.7K over 90 days · 100% sells
Short interest
Falling
3.13% of float · ▼ -8.4% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 44%
Range high $3
vs 200-day avg +7%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AUCATZYL Global Net Product Revenue | $71.9M | 1H 2026 | — |
|
|
|||
| Gross margin | 55% | Q2 2026 | — |
| U.S. Authorized Treatment Centers | 82 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUTL
this stock
Autolus Therapeutics plc
|
$493.73M | -10.1% | +496.0% | — | 3.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUTL | -3.8% | -15.2% | +20.1% | -7.7% | -10.1% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -5.7% | -16.9% | +8.8% | -9.9% | -24.3% |